These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35022812)

  • 1. Guideline adherence by physicians for management of glucocorticoid-induced osteoporosis in Japan: a nationwide health insurance claims database study.
    Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
    Osteoporos Int; 2022 May; 33(5):1097-1108. PubMed ID: 35022812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed initiation of anti-osteoporosis medications increases subsequent hip and vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
    Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
    Bone; 2022 Jul; 160():116396. PubMed ID: 35351673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
    Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
    Bone; 2023 Jan; 166():116605. PubMed ID: 36347433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Average daily glucocorticoid dose, number of prescription days, and cumulative dose in the initial 90 days of glucocorticoid therapy are associated with subsequent hip and clinical vertebral fracture risk: a retrospective cohort study using a nationwide health insurance claims database in Japan.
    Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Imano H; Ogawa S
    Osteoporos Int; 2024 May; 35(5):805-818. PubMed ID: 38267664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan.
    Moriwaki K; Fukuda H
    Osteoporos Int; 2019 Feb; 30(2):299-310. PubMed ID: 30610244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management and treatment of osteoporosis in patients receiving long-term glucocorticoid treatment: current status of adherence to clinical guidelines and related factors.
    Kirigaya D; Nakayama T; Ishizaki T; Ikeda S; Satoh T
    Intern Med; 2011; 50(22):2793-800. PubMed ID: 22082891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fracture risk associated with glucocorticoid-induced osteoporosis in Japan.
    Soen S; Kaku M; Okubo N; Onishi Y; Saito K; Kobayashi M
    J Bone Miner Metab; 2022 Jul; 40(4):636-647. PubMed ID: 35546370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Glucocorticoid and Bone. Updated Japanese guidelines for the management of glucocorticoid-induced osteoporosis].
    Suzuki Y
    Clin Calcium; 2014 Sep; 24(9):1309-18. PubMed ID: 25177003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond bone mineral density, FRAX-based tailor-made intervention thresholds for therapeutic decision in subjects on glucocorticoid: A nationwide osteoporosis survey.
    Yu SF; Chen JF; Chen YC; Lai HM; Ko CH; Chiu WC; Su FM; Hsu CY; Su BY; Wu CH; Cheng TT
    Medicine (Baltimore); 2017 Feb; 96(5):e5959. PubMed ID: 28151883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin D and bisphosphonate therapy in systemic lupus erythematosus patients who receive glucocorticoids: are we offering the best care?
    Sapkota S; Baig S; Hess T; O'Connell AM; Menk J; Shyne M; Fazeli P; Ensrud K; Shmagel A
    Lupus; 2020 Mar; 29(3):263-272. PubMed ID: 31996109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoporosis management among chronic glucocorticoid users: a systematic review.
    Albaum JM; Youn S; Levesque LE; Gershon AS; Cadarette SM
    J Popul Ther Clin Pharmacol; 2014; 21(3):e486-504. PubMed ID: 25527817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of fractures among patients receiving medications for type 2 diabetes or chronic obstructive pulmonary disease and glucocorticoid users according to the National Claims Database in Japan.
    Fujiwara S; Ishii S; Hamasaki T; Okimoto N
    Arch Osteoporos; 2021 Jun; 16(1):106. PubMed ID: 34191131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimates of hip fracture incidence in Japan using the National Health Insurance Claim Database in 2012-2015.
    Tamaki J; Fujimori K; Ikehara S; Kamiya K; Nakatoh S; Okimoto N; Ogawa S; Ishii S; Iki M;
    Osteoporos Int; 2019 May; 30(5):975-983. PubMed ID: 30648192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insufficient increase in bone mineral density testing rates and pharmacotherapy after hip and vertebral fracture: analysis of the National Database of Health Insurance Claims and Specific Health Checkups of Japan.
    Nakatoh S; Fujimori K; Ishii S; Tamaki J; Okimoto N; Ogawa S; Iki M
    Arch Osteoporos; 2021 Sep; 16(1):130. PubMed ID: 34510296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club.
    Devogelaer JP; Goemaere S; Boonen S; Body JJ; Kaufman JM; Reginster JY; Rozenberg S; Boutsen Y
    Osteoporos Int; 2006 Jan; 17(1):8-19. PubMed ID: 16217586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An observational study of glucocorticoid-induced osteoporosis prophylaxis in a national cohort of male veterans with rheumatoid arthritis.
    Caplan L; Hines AE; Williams E; Prochazka AV; Saag KG; Cunningham F; Hutt E
    Osteoporos Int; 2011 Jan; 22(1):305-15. PubMed ID: 20358362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insufficient persistence to pharmacotherapy in Japanese patients with osteoporosis: an analysis of the National Database of Health Insurance Claims and Specific Health Checkups in Japan.
    Nakatoh S; Fujimori K; Ishii S; Tamaki J; Okimoto N; Ogawa S; Iki M
    Arch Osteoporos; 2021 Sep; 16(1):131. PubMed ID: 34515872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Glucocorticoid-induced osteoporosis].
    Suzuki Y
    Nihon Rinsho; 2015 Oct; 73(10):1733-9. PubMed ID: 26529939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone mineral density measurement and osteoporosis treatment after a fragility fracture in older adults: regional variation and determinants of use in Quebec.
    Vanasse A; Dagenais P; Niyonsenga T; Grégoire JP; Courteau J; Hemiari A
    BMC Musculoskelet Disord; 2005 Jun; 6():33. PubMed ID: 15969760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.